Notice on expected shortage of Cefepime Kabi powder for solution for injection or infusion (cefepime)
16.11.2015
Fresenius Kabi d.o.o., the marketing authorisation holder for Cefepime Kabi powder for solution for injection or infusion (cefepime) à 1 and 2 g, has notified the Agency for Medicinal Products and Medical devices (HALMED) of an expected shortage of these medicinal products on the Croatian market.
The normalisation of the supply chain with this medicine is expected in January 2016.
Taking into account that there is no other authorised medicinal product in the Republic of Croatia with the same active substance, HALMED will, at wholesaler’s request during the shortage period, provide accords for enter/import of a medicinal product not authorised in Croatia.
